

1/21

A




FIG. 1

2/21

B




FIG. 1 (continued)




FIG. 2

B

ABCE1	EGR2	MT-CO2	PTGS2	Rpl39	TMEM126A
ADAMTS1	EGR3	MT-CO3	RNF2	Rps15a	UBE2D3
ARC	FXN	MT-ND1	Rpl10	Rps27l	UQCRC1
ATF3	IGF1	MT-ND2	Rpl24	RTN4	UQCRC2
BTG2	LOX	MT-ND3	Rpl26	RTN4IP1 (OPA10)	
CYCS	LRPPRC	MT-ND4	Rpl32	SERPINE1	
CYR61	MT-ATP6	NR4A1	Rpl37t	SLIRP	
EGR1	MT-ATP8	PSMA3	Rpl38	THBS1	

FIG. 2 (continued)

5/21




FIG. 3

6/21




FIG. 3 (continued)

7/21

A

Control (SCRAMBLE KD #5)




FIG. 4

8/21

B

LRPPRC KD (#21C)




FIG. 4 (continued)

9/21

C




FIG. 4 (continued)

10/21

D




FIG. 4 (continued)

11/21




FIG. 5

12/21




FIG. 5 (continued)




FIG. 6




FIG. 6 (continued)




FIG. 7




FIG. 7 (continued)




FIG. 8

B

Expression of mature oligodendrocyte gene markers after treatment with vehicle or 20 μ M exemplary TAT-FXN fusion protein




FIG. 8 (continued)




FIG. 9




FIG. 9 (continued)

21/21




FIG. 10